Skip to content
About
About
Join The Team
Management Team
Pipeline
Technology
Technology
Tavo
VLA
Combination Approach
Publications
Partnering
Patients
Patients
Resources
Together Against Cancer
Investors
Media & Videos
Contact
Menu Toggle
About
Menu Toggle
About
Join The Team
Management Team
Pipeline
Technology
Menu Toggle
Technology
Tavo
VLA
Combination Approach
Publications
Partnering
Patients
Menu Toggle
Patients
Resources
Together Against Cancer
Investors
Media & Videos
Contact
MEDIA
Media Inquiries
[email protected]
855-662-6732
Press Releases
OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022
December 05, 2022
OncoSec Announces Pricing of $3.5 Million Public Offering
November 30, 2022
OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma
November 15, 2022
VIEW ALL PRESS RELEASES
Video Feed
3D MOA Animation video
✕
OncoSec's VLA 3D MOA Animation
✕
TAVO Demonstration with Dr Algazi
✕
OncoSec at 2020 BIO CEO Panel
✕
Tumor Immunogenicity
✕
IAD Reel
✕
IAD Robert Andtbacka, M.D.
✕
Social Media
Twitter Feed
Featured Articles
Melanoma Research Alliance
From Dermatology to Treatment: Second Opinions, Clinical Trials & becoming Your Own Best Advocate
PharmaVoice
Women of the Week interview with OncoSec’s Chief Clinical Development Officer, Kellie Malloy Foerter
Annals of Oncology
Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients
Clinical Cancer Research
Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma.